Immunovant Stock Gets Higher EPS Forecast from HC Wainwright

Immunovant, Inc. (NASDAQ:IMVT – Free Report) – Stock analysts at HC Wainwright boosted their Q3 2027 EPS estimates for shares of Immunovant in a research note issued on Tuesday, November 10th. HC Wainwright analyst D. Tsao now forecasts that the company will post earnings per share of ($0.77) for the quarter, up from their prior estimate of ($0.78). HC Wainwright has a “Buy” rating on the stock. The consensus estimate for Immunovant’s current full-year earnings is ($2.49) per share. HC Wainwright also issued estimates for Immunovant’s FY2027 earnings at ($2.81) EPS, FY2028 earnings at ($3.46) EPS and FY2029 earnings at ($0.84) EPS.

Immunovant (NASDAQ:IMVT – Get Free Report) last posted its quarterly earnings data on Monday, November 9th. The company reported ($0.47) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.74) by $0.27. During the same period last year, the firm earned ($0.73) earnings per share.

A number of other analysts have also issued reports on the company. Truist Financial lifted their price target on Immunovant from $30.00 to $33.00 and gave the stock a “hold” rating in a research note on Tuesday, November 10th. Wall Street Zen upgraded Immunovant from a “sell” rating to a “hold” rating in a research report on Saturday, November 14th. Sanford C. Bernstein raised Immunovant to a “hold” rating in a research note on Wednesday, July 29th. JPMorgan Chase & Co. increased their price objective on Immunovant from $47.00 to $50.00 and gave the company an “overweight” rating in a research note on Tuesday, August 4th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Immunovant in a report on Tuesday, August 25th. Nine research analysts have rated the stock with a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $44.60.

Check Out Our Latest Report on Immunovant

Immunovant Price Performance

Shares of Immunovant stock opened at $32.49 on Wednesday. The business has a 50 day simple moving average of $32.17 and a two-hundred day simple moving average of $32.47. Immunovant has a 12 month low of $21.86 and a 12 month high of $45.42.

Institutional Investors Weigh In On Immunovant

Several hedge funds and other institutional investors have recently made changes to their positions in IMVT. BlackRock Inc. purchased a new position in Immunovant during the second quarter worth approximately $276,680,000. Two Seas Capital LP grew its holdings in Immunovant by 46.5% in the 3rd quarter. Two Seas Capital LP now owns 4,612,692 shares of the company’s stock valued at $155,817,000 after buying an additional 1,464,187 shares in the last quarter. ADAR1 Capital Management LLC grew its holdings in Immunovant by 8.0% in the 1st quarter. ADAR1 Capital Management LLC now owns 2,679,010 shares of the company’s stock valued at $66,547,000 after buying an additional 198,042 shares in the last quarter. Bank of America Corp DE acquired a new stake in shares of Immunovant in the 2nd quarter worth $45,521,000. Finally, Aberdeen Group plc increased its stake in shares of Immunovant by 2.6% in the 3rd quarter. Aberdeen Group plc now owns 879,334 shares of the company’s stock worth $29,704,000 after acquiring an additional 22,304 shares during the last quarter. Institutional investors and hedge funds own 47.08% of the company’s stock.

Insider Activity at Immunovant

In other Immunovant news, insider Christopher Van Tuyl sold 1,327 shares of the stock in a transaction dated Wednesday, October 7th. The shares were sold at an average price of $32.06, for a total value of $42,543.62. Following the completion of the sale, the insider owned 175,218 shares in the company, valued at approximately $5,617,489.08. This represents a 0.75% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Atul Pande sold 3,000 shares of the stock in a transaction dated Wednesday, November 11th. The shares were sold at an average price of $36.00, for a total transaction of $108,000.00. Following the completion of the sale, the director owned 116,731 shares of the company’s stock, valued at approximately $4,202,316. The trade was a 2.51% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 27,430 shares of company stock worth $895,852 in the last 90 days. 1.90% of the stock is owned by insiders.

About Immunovant

(Get Free Report)

Immunovant, Inc. is a clinical-stage biopharmaceutical company developing treatments for autoimmune diseases. Its research focuses on inhibiting the neonatal Fc receptor (FcRn), a pathway involved in maintaining levels of disease-causing antibodies. The company’s investigational medicines include batoclimab and IMVT-1402, both designed to reduce circulating antibodies. Immunovant has studied or evaluated these candidates for conditions including myasthenia gravis, Graves’ disease and other autoimmune disorders.

Read More

Earnings History and Estimates for Immunovant (NASDAQ:IMVT)

Receive News & Ratings for Immunovant Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunovant and related companies with MarketBeat.com's FREE daily email newsletter.